NLRP3 and Sepsis: Previous studies have shown that in conditions such as renal impairment (69), sepsis-induced myocardial injury (70), and asthma (71), glyburide reduces inflammation by inhibiting NLRP3 activation and decreasing levels of inflammatory mediators such as IL-1β and IL-18 (72).